TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00608582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation, Repetitive
Description: 10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation, Repetitive
Description: 10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
Study: NCT03577717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized cognitive training
Description: participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy
Description: participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
Study: NCT04050865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.4mg
Description: Ophthalmic Insert

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plug with no drug
Description: Ophthalmic Insert
Study: NCT02675361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition program
Description: Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
Study: NCT04174924

Intervention type: PROCEDURE
Intervention: Phakic intraocular lens (pIOL) explantation
Description: Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye.
Study: NCT01288859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free curcumin
Description: free curcumin in bread, dosage 1g/100g, 200g/day per 1 day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated curcumin
Description: encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated curcumin + PQG
Description: bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free cocoa polyphenol
Description: nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated cocoa polyphenols
Description: nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control nut cream
Description: nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
Study: NCT02526732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual training program
Description: Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
Study: NCT00642512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Description: 10 - 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: 8 - 16 mg

Intervention type: DRUG
Group type: OTHER
Intervention: dronabinol/ondansetron
Description: 10 - 20 mg/8 - 16 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03190473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES
Description: PCI with implantation of a DES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES
Description: PCI with implantation of a DES
Study: NCT03491644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titrated Oxygen
Description: Restrictive treatment with oxygen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Oxygen
Description: Liberal treatment with oxygen.
Study: NCT02210364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) 1 mg and 4 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 150 mg tablets
Study: NCT01402453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrinsic Motivation
Description: A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
Study: NCT03302338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAFE group
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: distilled water 20 ml/kg/day for maximum of 7 days.
Study: NCT02449200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
Study: NCT02265562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 minutes before the surgery 2 tablet of placebo inserted rectally
Study: NCT03321331

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lark (JITAI)
Description: Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MyFitnessPal (no JITAI)
Description: MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
Study: NCT00881387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV
Study: NCT04380402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40 mg tablet
Study: NCT01380340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seniors Early Intervention Planning and Discussion.
Description: The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
Study: NCT04907708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Euglycemic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Hypoglycemic agent
Study: NCT04001673

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist's intervention
Description: Information about bDMARDs management.
Study: NCT03724643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized wean
Description: Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
Study: NCT04088552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go4Life-Physical Activity/Exercise Program Workout to Go 5
Description: The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActuaYa Educational Sessions
Description: The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
Study: NCT02522494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: An educational intervention delivered prior to patients' visits with primary care physicians.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pamphlet
Description: An educational intervention delivered prior to patients' visits with primary care physicians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: An educational intervention delivered prior to patients' visits with primary care providers.
Study: NCT02291887

Intervention type: DRUG
Intervention: Ranibizumab
Description: Intravitreal injection of Ranibizumab

Intervention type: DRUG
Intervention: Aflibercept
Description: Intravitreal injection of Aflibercept
Study: NCT01443481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
Study: NCT00328510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTC frame

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic facemask

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Study: NCT01988311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin
Description: dose manipulation as described in the protocol
Study: NCT03750474

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: magnetic resonance elastography and shear wave elastography
Description: magnetic resonance elastography and shear wave elastography of the back muscles

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance elastography and shear wave elastography
Description: magnetic resonance elastography and shear wave elastography of the back muscles
Study: NCT01427920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
Study: NCT03235167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG DNA
Description: CpG DNA concentrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization (TACE) therapy for liver cancer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization (TACE) therapy for liver cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: CpG DNA vehicle
Study: NCT03979235

Intervention type: DIAGNOSTIC_TEST
Intervention: Motor function assessment
Description: perform motor function assessment by using scales, sEMG, and inertia sensors

Intervention type: DIAGNOSTIC_TEST
Intervention: Motor function assessment
Description: perform motor function assessment by using scales, sEMG, and inertia sensors
Study: NCT01717456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber supplements
Description: Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber supplements
Description: Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laxatives or anti-diarrheals
Description: Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tips on how to prevent fecal incontinence
Description: Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze.
Study: NCT03315871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C (M7824)
Description: Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C (M7824)
Description: Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
Study: NCT01717118

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Vaccines

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetravalent Vaccine
Study: NCT01605513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon
Description: PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
Study: NCT04217863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDP
Description: Guided Disclosure Protocol
Study: NCT04064034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Flow Assay (LFA)
Description: Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Flow Assay (LFA)
Description: Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Flow Assay (LFA)
Description: Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
Study: NCT03663231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene
Description: Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IND/IDE exempt device primarily water
Study: NCT00725452

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
Study: NCT03752684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Subjects will be instructed to ingest a controlled diet low in oxalate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderately high oxalate/low calcium diet
Description: Subjects will be instructed to ingest a controlled diet moderately high in oxalate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: Subjects will ingest live preparation of O. formigenes